Values First Advisors Inc. Trims Stake in Guardant Health, Inc. (NASDAQ:GH)

Values First Advisors Inc. lessened its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 21.8% during the second quarter, HoldingsChannel reports. The institutional investor owned 28,248 shares of the company’s stock after selling 7,863 shares during the quarter. Values First Advisors Inc.’s holdings in Guardant Health were worth $816,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in GH. Capital International Investors boosted its stake in shares of Guardant Health by 36.7% during the fourth quarter. Capital International Investors now owns 4,001,803 shares of the company’s stock worth $108,249,000 after buying an additional 1,074,452 shares during the period. Norges Bank purchased a new stake in shares of Guardant Health in the fourth quarter valued at about $25,520,000. Cadian Capital Management LP acquired a new position in shares of Guardant Health during the fourth quarter worth about $19,206,000. Mitsubishi UFJ Trust & Banking Corp purchased a new position in Guardant Health during the first quarter worth about $8,300,000. Finally, abrdn plc acquired a new stake in Guardant Health in the fourth quarter valued at about $9,362,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on GH shares. The Goldman Sachs Group boosted their target price on Guardant Health from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, July 17th. Stephens reissued an “overweight” rating and issued a $44.00 target price on shares of Guardant Health in a report on Friday, May 24th. Craig Hallum upped their price target on shares of Guardant Health from $28.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Bank of America raised their price objective on shares of Guardant Health from $28.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, July 18th. Finally, Citigroup upped their target price on shares of Guardant Health from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, Guardant Health currently has an average rating of “Moderate Buy” and an average price target of $39.27.

Guardant Health Price Performance

GH stock traded down $0.59 on Friday, reaching $27.95. The company had a trading volume of 3,085,052 shares, compared to its average volume of 2,066,684. The company’s fifty day moving average is $30.62 and its 200 day moving average is $24.24. The company has a market cap of $3.42 billion, a P/E ratio of -7.13 and a beta of 1.13. The company has a debt-to-equity ratio of 16.70, a quick ratio of 5.66 and a current ratio of 5.95. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $41.06.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.10). The company had revenue of $177.24 million during the quarter, compared to analysts’ expectations of $162.59 million. Guardant Health had a negative net margin of 76.34% and a negative return on equity of 246.47%. The firm’s revenue was up 29.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.67) earnings per share. On average, research analysts forecast that Guardant Health, Inc. will post -3.31 earnings per share for the current year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.